胶质母细胞瘤患者的当前临床管理。
Current clinical management of patients with glioblastoma.
机构信息
Department of Neurosurgery, Medical University of South Carolina, Charleston, South Carolina.
Deparment of Translational Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
出版信息
Cancer Rep (Hoboken). 2019 Dec;2(6):e1216. doi: 10.1002/cnr2.1216. Epub 2019 Sep 4.
BACKGROUND
Glioblastoma (GB) is the most aggressive primary brain tumor, historically resistant to treatment, and with overall fatal outcome.
RECENT FINDINGS
Recently, several molecular subgroups and rare genetic alterations have been described in GB. In this review article, we will describe the current clinical management of patients with GB in the United States, discuss selected next-generation molecular-targeted therapies in GB, and present ongoing clinical trials for patients with GB. This review is intended for clinical and preclinical researchers who conduct work on GB and would like to understand more about the current standard of treatment of GB patients, historical perspectives, current challenges, and ongoing and upcoming clinical trials.
CONCLUSIONS
GB is an extremely complex disease, and despite recent progress and advanced therapeutic strategies, the overall patient's prognosis remains dismal. Innovative strategies and integrative ways of approach to disease are urgently needed.
背景
胶质母细胞瘤（GB）是最具侵袭性的原发性脑肿瘤，历史上对治疗具有抗性，且整体预后为致命性的。
最近发现
最近，在 GB 中描述了几种分子亚群和罕见的遗传改变。在这篇综述文章中，我们将描述目前在美国对 GB 患者的临床管理，讨论 GB 中选定的下一代分子靶向治疗方法，并介绍正在进行的 GB 患者临床试验。该综述旨在为从事 GB 研究的临床和临床前研究人员提供帮助，使他们更深入地了解 GB 患者目前的治疗标准、历史观点、当前挑战以及正在进行和即将开展的临床试验。
结论
GB 是一种极其复杂的疾病，尽管最近取得了进展和先进的治疗策略，但总体患者预后仍然不佳。迫切需要创新的策略和综合的疾病处理方法。
Zotero 插件